MA39722A - Composition pour son utilisation dans une methode de traitement ou de prevention de l'anemie par l'inhibition de l'activine b et du gdf11 - Google Patents
Composition pour son utilisation dans une methode de traitement ou de prevention de l'anemie par l'inhibition de l'activine b et du gdf11Info
- Publication number
- MA39722A MA39722A MA039722A MA39722A MA39722A MA 39722 A MA39722 A MA 39722A MA 039722 A MA039722 A MA 039722A MA 39722 A MA39722 A MA 39722A MA 39722 A MA39722 A MA 39722A
- Authority
- MA
- Morocco
- Prior art keywords
- gdf11
- activin
- anemia
- inhibition
- prevention
- Prior art date
Links
- 108010059616 Activins Proteins 0.000 title 1
- 102100040898 Growth/differentiation factor 11 Human genes 0.000 title 1
- 101000893545 Homo sapiens Growth/differentiation factor 11 Proteins 0.000 title 1
- 102100026818 Inhibin beta E chain Human genes 0.000 title 1
- 239000000488 activin Substances 0.000 title 1
- 208000007502 anemia Diseases 0.000 title 1
- 230000005764 inhibitory process Effects 0.000 title 1
- 230000002265 prevention Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- General Chemical & Material Sciences (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Endocrinology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461969073P | 2014-03-21 | 2014-03-21 | |
| US201462021923P | 2014-07-08 | 2014-07-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA39722A true MA39722A (fr) | 2021-06-02 |
Family
ID=54145413
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA039722A MA39722A (fr) | 2014-03-21 | 2015-03-20 | Composition pour son utilisation dans une methode de traitement ou de prevention de l'anemie par l'inhibition de l'activine b et du gdf11 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US20160046690A1 (enExample) |
| EP (1) | EP3119418B1 (enExample) |
| JP (2) | JP2017509647A (enExample) |
| KR (2) | KR102520970B1 (enExample) |
| CN (1) | CN106659769A (enExample) |
| AU (3) | AU2015231022B2 (enExample) |
| CA (1) | CA2942954A1 (enExample) |
| MA (1) | MA39722A (enExample) |
| WO (1) | WO2015143403A1 (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8216997B2 (en) | 2008-08-14 | 2012-07-10 | Acceleron Pharma, Inc. | Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators |
| MX366336B (es) | 2012-11-02 | 2019-07-05 | Celgene Corp | Antagonistas de activina - actrii y usos para el tratar trastornos oseos y otros. |
| US10603359B2 (en) * | 2014-10-30 | 2020-03-31 | Acceleron Pharma Inc. | Methods and compositions using GDF15 polypeptides for increasing red blood cells |
| SMT202300166T1 (it) | 2014-12-03 | 2023-07-20 | Celgene Corp | Antagonisti di attivina- actrii e usi per il trattamento di sindrome mielodisplastica |
| MA41119A (fr) | 2014-12-03 | 2017-10-10 | Acceleron Pharma Inc | Méthodes de traitement de syndromes myélodysplasiques et d'anémie sidéroblastique |
| RS61881B1 (sr) | 2015-04-22 | 2021-06-30 | Biogen Ma Inc | Novi hibridni actriib proteini zamke za ligand za lečenje bolesti gubljenja mišića |
| US11123430B2 (en) | 2015-11-04 | 2021-09-21 | Acceleron Pharma Inc. | Methods for increasing red blood cell levels and treating ineffective erythropoiesis |
| CA3005975A1 (en) | 2015-11-23 | 2017-06-01 | Acceleron Pharma Inc. | Methods for treating eye disorders |
| MX2019001043A (es) | 2016-07-27 | 2019-09-26 | Acceleron Pharma Inc | Metodos y composiciones para el tratamiento de la mielofibrosis. |
| US20190218262A1 (en) * | 2016-09-15 | 2019-07-18 | Acceleron Pharma Inc. | Twisted gastrulation polypeptides and uses thereof |
| WO2018067874A1 (en) | 2016-10-05 | 2018-04-12 | Acceleron Pharma Inc. | Variant actriib proteins and uses thereof |
| JOP20190085A1 (ar) | 2016-10-20 | 2019-04-17 | Biogen Ma Inc | طرق علاج الضمور العضلي ومرض العظام باستخدام بروتينات احتجاز مركب ترابطي actriib هجين حديثة |
| EP3538123A4 (en) | 2016-11-10 | 2020-10-14 | Keros Therapeutics, Inc. | ACTIVIN RECEPTOR TYPE IIA VARIANTS AND THEIR METHODS OF USE |
| JP7496686B2 (ja) | 2017-06-14 | 2024-06-07 | セルジーン コーポレイション | 骨髄増殖性腫瘍関連骨髄線維症及び貧血を治療するための方法 |
| CN107828719B (zh) * | 2017-09-14 | 2020-05-19 | 暨南大学 | Gdf11在脂肪间充质干细胞成骨分化中的应用 |
| CA3082146A1 (en) | 2017-11-09 | 2019-05-16 | Keros Therapeutics, Inc. | Activin receptor type iia variants and methods of use thereof |
| CN120399032A (zh) | 2018-01-12 | 2025-08-01 | 科乐斯疗法公司 | 激活素受体iib型变体及其使用方法 |
| EP3788065B1 (en) | 2018-04-30 | 2025-08-27 | The Children's Hospital Of Philadelphia | Improving anemias by combining agents |
| EP3790572A4 (en) | 2018-05-09 | 2022-03-16 | Keros Therapeutics, Inc. | ACTIVIN RECEPTOR TYPE IIA VARIANTS AND METHODS OF USE THEREOF |
| JP7663882B6 (ja) * | 2020-01-20 | 2025-06-10 | ルダキュア コーポレーション | Ｔｒｐｖ１活性媒介疾患治療用の薬学的組成物 |
| EP4121088A4 (en) | 2020-03-20 | 2024-07-03 | Keros Therapeutics, Inc. | Methods of using activin receptor type iib variants |
| EP4514971A1 (en) * | 2022-04-29 | 2025-03-05 | University Of Massachusetts | Selective rna-modulating agents |
| WO2025040002A1 (zh) * | 2023-08-21 | 2025-02-27 | 苏州炫景生物科技有限公司 | 靶向inhbe基因的双链寡核苷酸、缀合物、组合物及其用途 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA201100642A1 (ru) * | 2005-04-25 | 2011-12-30 | Пфайзер Инк. | Антитела к миостатину |
| US8128933B2 (en) * | 2005-11-23 | 2012-03-06 | Acceleron Pharma, Inc. | Method of promoting bone growth by an anti-activin B antibody |
| EP2468291B1 (en) * | 2006-12-18 | 2017-11-22 | Acceleron Pharma, Inc. | Activin-actrii antagonists and uses for increasing red blood cell levels |
| JP5922928B2 (ja) * | 2008-08-14 | 2016-05-24 | アクセルロン ファーマ， インコーポレイテッド | 赤血球レベルを高めるためのｇｄｆトラップの使用 |
| US8216997B2 (en) * | 2008-08-14 | 2012-07-10 | Acceleron Pharma, Inc. | Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators |
| CN102482339B (zh) * | 2009-06-08 | 2015-06-17 | 阿塞勒隆制药公司 | 用于增加产热脂肪细胞的方法 |
| ES2796121T3 (es) * | 2009-08-13 | 2020-11-25 | Acceleron Pharma Inc | Uso combinado de trampas de GDF y activadores del receptor de la eritropoyetina para aumentar los niveles de glóbulos rojos |
| WO2012027065A2 (en) * | 2010-08-27 | 2012-03-01 | Celgene Corporation | Combination therapy for treatment of disease |
| CA2852683A1 (en) * | 2011-10-17 | 2013-04-25 | Acceleron Pharma, Inc. | Methods and compositions for treating ineffective erythropoiesis |
| WO2013164444A1 (en) * | 2012-05-03 | 2013-11-07 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Method and pharmaceutical composition for use in the treatment and diagnotic of anemia of inflammation |
| CN104981250A (zh) * | 2012-10-24 | 2015-10-14 | 细胞基因公司 | 用于治疗贫血的方法 |
-
2015
- 2015-03-20 KR KR1020227044659A patent/KR102520970B1/ko active Active
- 2015-03-20 CN CN201580024704.5A patent/CN106659769A/zh active Pending
- 2015-03-20 MA MA039722A patent/MA39722A/fr unknown
- 2015-03-20 EP EP15765863.4A patent/EP3119418B1/en active Active
- 2015-03-20 CA CA2942954A patent/CA2942954A1/en active Pending
- 2015-03-20 WO PCT/US2015/021880 patent/WO2015143403A1/en not_active Ceased
- 2015-03-20 KR KR1020167029253A patent/KR20160127148A/ko not_active Ceased
- 2015-03-20 JP JP2016557982A patent/JP2017509647A/ja not_active Withdrawn
- 2015-03-20 AU AU2015231022A patent/AU2015231022B2/en not_active Ceased
- 2015-03-20 US US14/664,651 patent/US20160046690A1/en not_active Abandoned
-
2020
- 2020-04-24 JP JP2020077142A patent/JP7154250B2/ja active Active
- 2020-07-02 US US16/919,377 patent/US20210155672A1/en not_active Abandoned
-
2021
- 2021-01-19 AU AU2021200301A patent/AU2021200301A1/en not_active Abandoned
-
2023
- 2023-08-23 AU AU2023219885A patent/AU2023219885A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU2021200301A1 (en) | 2021-03-18 |
| CA2942954A1 (en) | 2015-09-24 |
| KR102520970B1 (ko) | 2023-04-12 |
| EP3119418A1 (en) | 2017-01-25 |
| JP2020111621A (ja) | 2020-07-27 |
| EP3119418B1 (en) | 2022-02-23 |
| AU2023219885A1 (en) | 2023-09-14 |
| US20210155672A1 (en) | 2021-05-27 |
| AU2015231022A1 (en) | 2016-09-29 |
| WO2015143403A1 (en) | 2015-09-24 |
| JP7154250B2 (ja) | 2022-10-17 |
| US20160046690A1 (en) | 2016-02-18 |
| EP3119418A4 (en) | 2018-01-03 |
| CN106659769A (zh) | 2017-05-10 |
| KR20230004942A (ko) | 2023-01-06 |
| JP2017509647A (ja) | 2017-04-06 |
| KR20160127148A (ko) | 2016-11-02 |
| AU2015231022B2 (en) | 2021-02-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA39722A (fr) | Composition pour son utilisation dans une methode de traitement ou de prevention de l'anemie par l'inhibition de l'activine b et du gdf11 | |
| EP3374502A4 (en) | METHOD FOR THE TREATMENT OF CORNEAL DYSTROPHIES | |
| EP3302379A4 (en) | COMPOSITIONS AND METHOD FOR THE TREATMENT OF PTERYGIUM | |
| EP3347469A4 (en) | METHOD AND COMPOSITIONS FOR TREATING GLAUCOMA | |
| EP3368559A4 (en) | COMPOSITIONS AND METHODS FOR TREATING CANCER | |
| EP3233878A4 (en) | PHOSPHORAMIDATE FOR THE TREATMENT OF HEPATITIS C VIRUS | |
| EP3380200A4 (en) | COMPOSITIONS FOR TREATING THE HAIR | |
| EP3377516A4 (en) | METHOD AND COMPOSITIONS FOR THE TREATMENT OF CANCER | |
| EP3341391A4 (en) | COMPOSITIONS AND METHODS OF PAIN TREATMENT | |
| EP3503890A4 (en) | USE OF PRIDOPIDIN FOR THE TREATMENT OF DYSTONIA | |
| EP3362065A4 (en) | COMBINATION THERAPY FOR THE TREATMENT OF MALIGNITIES | |
| EP3380063A4 (en) | COMPOSITIONS FOR TREATING THE HAIR | |
| EP3334432A4 (en) | CERDULATINIB FOR THE TREATMENT OF MYELOMA | |
| EP3353204A4 (en) | METHOD AND COMPOSITIONS FOR THE TREATMENT OF CANCER | |
| MA43230A (fr) | Méthodes et compositions pour le traitement d'une épidermolyse bulleuse | |
| EP3386967A4 (en) | COMBINATIONS FOR TREATING KIDNEY STONES | |
| EP3522865A4 (en) | METHOD AND COMPOSITIONS FOR TREATING STRIAE DISTENSAE | |
| EP3429609A4 (en) | COMPOSITIONS AND METHOD FOR TREATING DEFECTS OF COLLAGEN TYPE VII | |
| EP3365014A4 (en) | METHOD AND COMPOSITIONS FOR TREATING SYSTEMIC MASTO CYTOSIS | |
| EP3386593A4 (en) | IMMUNOMODULATING COMPOSITION FOR TREATMENT | |
| MA45973A (fr) | Combinaisons d'inhibiteurs de btk pour le traitement du myélome multiple | |
| EP3329929A4 (en) | PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF DRY EYES | |
| EP3331545A4 (en) | FOR EXTRACELLULAR HEMICAN DOMAIN SPECIFIC MEANS FOR THE TREATMENT OF SEPSIS | |
| EP3302474A4 (en) | COMPOSITIONS FOR THE TREATMENT OF ATROPHIC VAGINITIS, PERI- AND POSTMENOPAUSAL DYSPAREUNIA AND / OR OOPHORECTORATED WOMEN AND TREATMENT METHODS THEREWITH | |
| EP3373922A4 (en) | COMPOSITIONS AND METHODS FOR TREATING HOMOCYSTINURIA |